Chronic myeloid leukemia (CML) is one of the most common leukemias occurring in the
adult population. The course of CML is divided into three phases: the chronic phase, the …

Chronic myelogenous leukemia (CML) requires the BCR/ABL tyrosine kinase for disease
onset and maintenance. As a result, CML can be successfully treated with tyrosine kinase …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

Chronic myeloid leukemia (CML) is a myeloproliferative disorder that affects 5000 new
patients per year in the United States. Prior to 10years ago, durable remission was rare and …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, characterized by the
unrestrained expansion of pluripotent hematopoietic stem cells. CML was the first …

Purpose of review In this review, we emphasize up-to-date practical cytogenetic and
molecular aspects of chronic myeloid leukemia (CML) and summarize current knowledge on …

Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …

The BCR-ABL1 fusion gene, which causes aberrant kinase activity and uncontrolled cell
proliferation, is the hallmark of chronic myeloid leukemia (CML). The development of …

The treatment of chronic myelogenous leukemia (CML) has been revolutionized by the
development of the small-molecule tyrosine kinase inhibitor imatinib. The primary target for …

Deregulated activity of BCR-ABL1, a nonreceptor tyrosine kinase encoded by the fusion
gene resulting from the t (9; 22)(q34; q11) chromosomal translocation, is thought to be the …